Small-Molecule Antibiotics Inhibiting tRNA-Regulated Gene Expression Is a Viable Strategy for Targeting Gram-Positive...

Area of Science:

• Microbiology
• Molecular Biology
• Drug Discovery

Background:

• Antibiotic resistance necessitates novel therapeutic strategies.
• The T-box riboswitch regulates essential genes in Gram-positive bacteria.
• Small-molecule drugs targeting T-boxes offer a potential avenue for new antibacterial agents.

Purpose of the Study:

• To develop and evaluate novel analogs of the T-box targeting drug PKZ18.
• To assess the efficacy, safety, and synergistic potential of these analogs against resistant bacteria.
• To investigate the mechanism of action and resistance development.

Main Methods:

• Synthesis and characterization of PKZ18 analogs.
• Determination of minimum inhibitory concentrations (MICs) and bactericidal effects.
• Eukaryotic cell cytotoxicity assays.
• Synergy testing with aminoglycosides.
• RNA sequencing to analyze gene expression changes.

Main Results:

• PKZ18 analogs demonstrated improved MICs and bactericidal activity against MRSA.
• Analogs showed reduced cytotoxicity compared to PKZ18.
• Synergistic effects were observed with aminoglycosides, enhancing therapeutic windows.
• RNA sequencing confirmed targeted regulation of T-box controlled genes with low resistance development.

Conclusions:

• PKZ18 analogs are potent antibacterial agents with improved safety profiles.
• Synergy with aminoglycosides broadens their therapeutic applicability.
• The multifaceted targeting and low resistance potential make these analogs promising candidates for clinical development.